Inicio › Enfermedad de Crohn › Luisiana
Ensayos clínicos de Enfermedad de Crohn en Luisiana
11 estudios sobre Enfermedad de Crohn buscan participantes en Luisiana.
Ciudades en Luisiana
- Lafayette7 estudios
- Metairie5 estudios
- Shreveport3 estudios
- Monroe3 estudios
- New Orleans3 estudios
- Baton Rouge3 estudios
Texto oficial del estudio (inglés)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
- Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
- Willis-Knighton Medical Center /ID# 280572, Shreveport
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 2 oct 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
- Combined Gastro LLC, Lafayette
- GI Alliance, Metairie
ReclutandoFase 4
Edades de 18 a 80 · Todos los sexos · Actualizado el 30 sept 2026 · NCT06581328A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
- Delta Research Partners, LLC, West Monroe
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
ReclutandoFase 3
Edades de 18 a 70 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Tandem Intermediate, LLC - Houma-Site Number: 8400034, Houma
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- y 4 más
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 23 sept 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- GI Alliance - Metairie-Site Number: 8400124, Metairie
- y 1 más
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 23 sept 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Tandem Clinical Research, Houma
ReclutandoFase 2
Edades de 18 a 85 · Todos los sexos · Actualizado el 22 sept 2026 · NCT06226883A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance, Metairie
- Tulane University, New Orleans
ReclutandoFase 4
Edades de 18 a 70 · Todos los sexos · Actualizado el 9 sept 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07577843A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Lafayette
- Mirador Therapeutics Selected Site, Marrero
- Mirador Therapeutics Selected Site, Shreveport
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 12 mar 2026 · NCT07113522De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.